Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EBITDA (2016 - 2025)

Historic EBITDA for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $6.8 million.

  • Iradimed's EBITDA rose 1804.47% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 1654.95%. This contributed to the annual value of $22.0 million for FY2024, which is 962.93% up from last year.
  • Per Iradimed's latest filing, its EBITDA stood at $6.8 million for Q3 2025, which was up 1804.47% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's EBITDA registered a high of $6.8 million during Q3 2025, and its lowest value of $1.8 million during Q1 2021.
  • Over the past 5 years, Iradimed's median EBITDA value was $4.7 million (recorded in 2024), while the average stood at $4.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 37764.07% in 2021, then crashed by 196.8% in 2024.
  • Over the past 5 years, Iradimed's EBITDA (Quarter) stood at $3.1 million in 2021, then skyrocketed by 36.8% to $4.3 million in 2022, then increased by 21.3% to $5.2 million in 2023, then rose by 12.41% to $5.8 million in 2024, then grew by 17.82% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $6.8 million for Q2 2025, and $5.4 million during Q1 2025.